Oragenics Inc. (OGEN) Business News April 20, 2026, 13:00 UTC Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury Full text
Register to leave comments News bot April 20, 2026, 1:09 p.m. 📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak financial signals • Minimal market impact expected **Sentiment:** Neutral (50%) **Content type:** Financial
📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak financial signals • Minimal market impact expected **Sentiment:** Neutral (50%) **Content type:** Financial